Ovulation Inducing Drugs Global Market Report 2024

The ovulation inducing drugs market size has grown strongly in recent years. It will grow from $4.11 billion in 2023 to $4.42 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth observed during the historical period can be attributed to the development of clomiphene citrate, the introduction of letrozole, regulatory approvals, standardization, and the emergence of ovulation predictor kits.

The ovulation inducing drugs market size is expected to see strong growth in the next few years. It will grow to $5.7 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The anticipated growth in the forecast period can be attributed to changing lifestyles and delayed childbearing, the integration of digital health, expanding market reach, increasing infertility rates, and the adoption of customized treatment regimens. Major trends expected during the forecast period include personalized treatment approaches, advancements in reproductive endocrinology, non-invasive fertility monitoring, a rising demand for assisted reproductive technologies, and the development of novel drug formulations.

The anticipated increase in the prevalence of women's infertility is poised to drive the expansion of the ovulation-inducing drug market. Women's infertility, characterized by the inability to conceive or carry a pregnancy to full term despite regular unprotected sexual intercourse, affects a significant percentage of women aged 15 to 44. Ovulation-inducing drugs, designed to address issues of irregular or absent ovulation, target hormonal pathways involved in the ovulation process, stimulating the release of mature eggs from the ovaries. For example, data from the Centers for Disease Control and Prevention reveals that approximately 10% of women in the US, totaling 6.1 million, face difficulties becoming pregnant. Additionally, CCRM Management Company LLC reports that infertility impacts 1 in 4 couples globally, with a yearly increase of 5% to 10%. Consequently, the growing prevalence of women's infertility acts as a key driver for the ovulation-inducing drug market.

The surge in patients opting for in vitro fertilization (IVF) is anticipated to fuel the ovulation-inducing drugs market's growth. IVF, a series of complex procedures aiding individuals and couples with fertility challenges, involves the use of ovulation-inducing drugs to stimulate ovaries and enhance egg production for retrieval. This approach is integral to optimizing the success rate of IVF procedures. Notably, a report from the Human Fertilization and Embryology Authority indicates an increase in IVF and donor insemination treatments in the UK, with around 55,000 people receiving such treatments in 2023. This figure represents a rise from approximately 53,000 patients in 2020, underscoring the upward trend in IVF utilization and subsequently contributing to the growth of the ovulation-inducing drugs market.

The development of alternative treatments is expected to pose a challenge to the ovulation-inducing drugs market. Alternatives such as Tamoxifen, complementary and alternative medicine (CAM), fertility surgery (FS), and IVF provide women with additional options for addressing ovulation disorders and enhancing the likelihood of pregnancy. The emergence of these alternative treatments introduces heightened competition to the ovulation-inducing drugs market. For example, the introduction of injected treatments such as Gonadotropins, specifically human menopausal gonadotropin (hMG) and follicle-stimulating hormone (FSH), has provided alternatives that stimulate ovarian activity. This variety of options in the market poses a restraint on the growth of ovulation-inducing drugs.

Major companies in the ovulation-inducing drugs market are proactively developing innovative drugs such as Cetrorelix acetate to secure approvals for treating women undergoing controlled ovarian stimulation. Cetrorelix acetate for injection, a gonadotropin-releasing hormone (GnRH) antagonist, has gained FDA approval, demonstrating its efficacy in preventing premature ovulation in women undergoing in vitro fertilization (IVF). In August 2022, Akorn Operating Company LLC received FDA approval for a generic version of cetrorelix acetate for injection, marking a significant advancement in fertility treatment. This development is aligned with the ongoing efforts of pharmaceutical companies, such as Akorn, to address infertility through innovative drugs.

In January 2021, Koninklijke Philips N.V, a health technology company, collaborated with Merck & Co. Inc., a pharmaceutical company specializing in ovulation-inducing drugs. This partnership aims to enhance the success rates of fertility treatments and ease the path to parenthood for couples grappling with infertility challenges. Overall, these strategic endeavors demonstrate the commitment of major companies to innovate and drive advancements in the ovulation-inducing drugs market.

Major companies operating in the ovulation inducing drugs market report are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Abbvie Inc., Novartis AG, Bayer AG, Sanofi SA, Abbott Laboratories, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical Inc., Mylan N.V, Astellas Pharma Inc., Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Dr Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Endo International Inc., Ferring Pharmaceuticals Inc., Lupin Limited, LIVZON Pharmaceutical Group Inc., Torrent Pharmaceuticals Ltd., Gedeon Richter plc, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Zydus Pharmaceuticals (USA) Inc., Serum Institute of India Ltd., EMD Serono Inc., Cipla Inc.

North America was the largest region in the ovulation-inducing drugs market in 2023. The regions covered in the ovulation inducing drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the ovulation inducing drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ovulation-inducing drugs market consists of sales of clomiphene citrate (Clomid), letrozole (Femara), gonadotropins, human chorionic gonadotropin (hCG), bromocriptine (Cycloset, Parlodel). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary types of ovulation-inducing drugs include hormones and therapeutic drugs. Hormone drugs are medications designed to modify or mimic the effects of naturally occurring hormones in the body. They can be administered through oral, topical, and other routes and are utilized by various end-users, including hospitals, homecare, specialty clinics, and others.

The ovulation-inducing drug market research report is one of a series of new reports that provides ovulation-inducing drug market statistics, including ovulation-inducing drug industry global market size, regional shares, competitors with a ovulation-inducing drug market share, detailed ovulation-inducing drug market segments, market trends and opportunities, and any further data you may need to thrive in the ovulation-inducing drug industry. This ovulation-inducing drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.